KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
For its part, Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics. Its subsidiary KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products since 1997. KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. (OTC:KONEF), has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelics subsidiary of Creso Pharma (OTC:COPHF) developing phase 2 clinical trials to test the efficacy of psilocybin on treatment-resistant post traumatic stress disorder (PTSD).
KGK Science Inc.，迷幻医疗保健研究和提供商的子公司幸福数字科学公司(场外交易代码：KONEF)，已与以下公司签订研究服务协议Halucenex生命科学公司。，迷幻药的子公司Creso Pharma(场外交易代码：COPHF)开发第二阶段临床试验以测试裸盖菇素治疗难治性创伤后应激障碍的疗效观察
The deal involves KGK performing research services, including the development of the clinical trial protocol, preparations towards the phase 2 trials, data management and validation, statistical analysis and drafting of the final report.
这笔交易涉及KGK提供研究服务包括制定临床试验方案、筹备第二阶段试验、数据管理和验证、统计分析和起草最终报告。
Creso Pharma usually works with cannabis, bringing pharmaceutical expertise and methodological rigor to their high-quality, GMP products, offering from cannabis to hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.
Creso Pharma通常用于大麻，为其高质量的GMP产品带来制药专业知识和方法上的严谨，提供从大麻到大麻衍生的治疗性、保健品和生活方式产品，为人类和动物健康提供广泛的患者和消费者接触。
For its part, Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics. Its subsidiary KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products since 1997.
就其本身而言，WellBeing Digital是一家以证据为基础的精神保健公司，专注于开发和实施创新的临床治疗解决方案，包括迷幻药物和数字疗法。其子公司KGK是一家总部设在安大略省伦敦的北美合同研究机构，自1997年以来主要提供高质量的临床研究试验，重点是营养食品和新兴保健产品。
As Wellbeing and KGK's CEO Najla Guthrie stated: "Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets. This marks an important step in moving the industry that much closer to creating alternative medicines for a growing population base."
AS福祉和KGK的首席执行官纳吉拉·格思里声明说：“在过去的25年里，我们成功地帮助了数百家公司进行了定制设计的临床试验，并声称实施了有效地将产品推向全球市场的证实策略。这标志着该行业朝着为不断增长的人口基础创造替代药物迈出了重要的一步。”
On his behalf, Halucenex CEO and founder Bill Flemming added: "KGK is a leading contract research organization, offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries. We are confident that KGK's role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions."
以他的名义，Halucenex首席执行官兼创始人比尔·弗莱明KGK是一家领先的合同研究组织，为营养食品、大麻、大麻和迷幻药行业提供高质量的临床研究试验和专家监管支持。我们相信，KGK的作用将使我们在创造替代治疗解决方案方面取得相当大的进展，以取代目前的药物干预。
Photo Courtesy of Geralt Sergei Tokmakov on Pixabay.
照片由Geralt Sergei Tokmakov在Pixabay上提供。
